Cosmo Pharmaceuticals N.V. Aandelen EO -,26
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
19.84%
Market Cap
1.22 Bil.
P/E Ratio
0.00
Dividend Yield
1.84 %
Earnings per Share
-0.23 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 75.5 G | 0 Units |
| PRICE DETERMINATION TIME | 06/10/2026 / 09:56:13 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 77.4 | 73.6 |
| PREV. DAY'S PRICE | 75.1 | (06/09) |
| CHANGE DAY BEFORE | +0.40 | 0.53 % |
| 52 WEEK HIGH / LOW | 137 (02/04) | 57 (08/07) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 1.22 | 0.08 | -0.23 | 8.15 | -0.31 |
| DIVIDENDS PER SHARE | 2.27 | 2.10 | 2.07 | 2.01 | 2.01 |
| DIVIDEND YIELD IN % | - | - | 1.84 % | 3.02 % | 3.83 % |
| DIVIDEND GROWTH IN % | - | - | 2.61 % | 0.47 % | 96.58 % |
| PRICE - EARNINGS RATIO | 65.01 | 970.44 | - | 8.19 | - |
| PRICE - BOOK RATIO | - | - | 3.80 | 2.18 | 2.08 |
| PRICE - SALES RATIO | - | - | 17.21 | 4.10 | 9.09 |
| PRICE - CASH FLOW RATIO | - | - | - | 6.73 | 28.05 |
Master Data
| WKN | A2AJ68 |
| ISIN | NL0011832936 |
| SYMBOL | C43 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | COSMO PHARMACEUT. EO-,26 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Swiss Franc |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 16.19 Mil. |
| MARKET CAPITALISATION | 1.22 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -3.21 % | -5.74 % | -30.73 % | -27.40 % | 19.84 % | - | - | -33.19 % |
| HIGH | 81.00 | 88.50 | 119.80 | 137.00 | 137.00 | - | - | 137.00 |
| LOW | 73.60 | 73.60 | 73.60 | 73.60 | 57.00 | - | - | 73.60 |
Dividend
per share
Company profile
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.